Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Phase 3
Terminated
- Conditions
- Multiple Myeloma Stage I
- Interventions
- Dietary Supplement: Calcium / Vitamin D
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 143
- Registration Number
- NCT00171925
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT00171314
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
Phase 2
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00170911
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
Phase 3
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT00170833
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Phase 3
Completed
- Conditions
- Transfusional Iron Overload in β-thalassemia
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 506
- Registration Number
- NCT00171210
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Phase 2
Terminated
- Conditions
- Primary Breast Cancer
- Interventions
- Drug: Zoledronic acid + Calcium/Vitamin D
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT00172068
- Locations
- 🇩🇪
Novartis Invstigative Site, Bielefeld, Germany
🇩🇪Novartis Investigative Site, Tuebingen, Germany
Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT00171808
- Locations
- 🇩🇪
Ebersberg, Germany, Hamburg, Germany
🇩🇪Novartis Investigative Site, Tuebingen, Germany
🇩🇪Tuebingen, Germany, Heidelberg, Germany
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 218
- Registration Number
- NCT00172055
- Locations
- 🇧🇪
Novaris Investigative Site, Libramont, Belgium
🇧🇪Novartis Investigative Site, Woluwe-Saint-Lambert, Belgium
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
Phase 4
Completed
- Conditions
- Heart Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00170859
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
Phase 4
Terminated
- Conditions
- HypertensionDiabetic Nephropathy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00171119
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
© Copyright 2025. All Rights Reserved by MedPath